anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clinical experience with Lexapro in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Lexapro in patients with diseases or conditions that produce altered metabolism or hemodynamic responses.

Lexapro has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing.

In subjects with hepatic impairment, clearance of racemic citalopram was decreased and plasma concentrations were increased. The recommended dose of Lexapro in hepatically impaired patients is 10 mg daily [see Dosage and Administration (2.5) and Use in Specific Populations (8.6)].

Because escitalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Lexapro, however, it should be used with caution in such patients [see Dosage and Administration (2.5) and Use in Specific Populations (8.7)].
The invention herein comprises a polymer bilayer which eliminates the spontaneous release of an active molecule by ion exchange. The spontaneous release is slowed by the application of a second polymer layer to the top of the electroactive polymer. The electroactive bilayer is preferably polypyrrole. The second polymer layer is preferably poly(vinyl butyral), poly(vinyl acetate) or nafion. This second layer stops the spontaneous release of the active molecule. The active molecule will usually be a pharmaceutical agent or drug. This bilayer allows a more effective controlled drug delivery system wherein the quantities and timing of the drugs can be given to the human being/animal patient with a high degree of certainty and predictability.
Varicose veins and heart failure (HF) are increasingly prevalent. Although numbers of observational studies have indicated that varicose veins might contribute to the risk of HF, the causal relationship between them remains unclear due to the uncontrolled confounding factors and reverse causation bias. Therefore, this study aimed to explore the potential causal relationship between varicose veins and HF. Based on publicly released genome-wide association studies (GWAS), gene correlation was assessed using linkage disequilibrium score (LDSC) regression, and we conducted a two-sample Mendelian randomization (TSMR) analysis to infer the causal relationship. We performed the Inverse variance weighted (IVW) method as the primary analysis, and used Weighted median, MR-Egger, weighted mode, simple mode, and MR-pleiotropy residual sum and outlier (MR-PRESSO) methods to detect and correct for horizontal pleiotropy. LDSC revealed there was a positive genetic correlation between varicose veins and HF (rg = 0.1726184, Se = 0.04511803, P = .0001). The results of the IVW method indicated that genetically predicted varicose veins were associated with an increased risk of HF (odds ratio (OR) = 1.03; 95% confidence interval (CI): 1.01-1.06; P = .009). Our findings illustrated the significant causal effect of varicose veins on HF, suggesting that people with varicose veins might have a higher risk of HF. The results provided a novel and important perspective into the development mechanism of HF.
Participants randomized to this arm will receive gabapentin beginning on evening of the first day of radiation treatment at a dose of 600 mg. Gabapentin will continue to be taken twice a day (morning and evening) for the next 4 days of radiation treatment at increasing doses (up to 900 mg). Participants will continue to receive standard best supportive care medications as per their treating physician's recommendation.
INTRODUCTION: Intentional physical self-injury (IPSI) is a pressing health challenge and there is little awareness of injury patterns, management and outcomes. This study examines IPSI's epidemiological and clinical aspects in one major Auckland hospital, highlighting demography, injury patterns and implications for clinical practice and prevention.
METHODS: Using Auckland City Hospital Trauma Registry data, a retrospective, descriptive study was conducted covering adult patients admitted from January 2015 to December 2019. It assessed demographic characteristics, injury patterns and outcomes, using Mann-Whitney U tests, Fisher's exact tests and Chi-squared tests.
RESULTS: Among 137 IPSI admissions, 92 (67%) required surgery, and 24% experienced post-operative complications. Major trauma was identified in 39 (28.5%) admissions. Discharge destinations varied, with only 64 (47%) patients returning home unassisted. Injury severity did not significantly vary across sex, age or injury event location. Major injuries often resulted from falls (19 of 39) and minor injuries from lacerations/stabs (73 of 98).
CONCLUSIONS: IPSI represents a significant challenge to Auckland health services, with a notable burden of care. The study highlights the need for targeted interventions to reduce the incidence of IPSI and improve outcomes. It underscores the importance of multidisciplinary approaches to care, integrating surgical, mental health and rehabilitative services.
LY01610(Irinotecan Hydrochloride Liposome Injection),Patients were enrolled in one to three cohorts to receive LY01610 every 2 weeks, initial 30 subjects will be included in each cohort and the number of the cases could be adjusted. Subjects will receive LY01610 start with 60 mg/m2 every 2 weeks，when the sixth subjects of the current cohort completed 14 days safety observation of the first LY01610 administration, the investigators will evaluate the ongoing dose tolerance. If the investigator and the sponsor jointly believe that other doses can provide greater potential benefits for patients while ensuring safety and benefit, other appropriate cohorts could be explored (such as 80, 90 and 100 mg/m2, etc.) Subjects will receive the LY01610 monotherapy until occurrence of progressive disease (PD), death, intolerable toxicity reaction, withdrawal of informed consent, conduct of other antitumor therapy or completion of the whole study.
Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
Treatment should consist of those general measures employed in the management of overdosage with any antidepressant.

  


Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.

  


Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known.

  


In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose. Telephone numbers for certified poison control centers are listed in the Physicians' Desk Reference® (PDR).
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a plaster for treating traumatic injury and a preparation method thereof. The plaster for treating traumatic injury mainly comprises the following components in parts by weight: 50-55 parts of ephedra, 50-55 parts of rhizoma kaempferiae, 50-55 parts of rehmannia, 50-55 parts of cortex moutan, 50-55 parts of pericarpium citri reticulatae, 50-55 parts of galangal, 50-55 parts of medicinal cyathula root, 50-55 parts of salvia miltiorrhiza, 55-65 parts of teasel root, 50-55 parts of eucommia bark, 55-65 parts of ligusticum wallichii, 55-65 parts of red paeony root, 55-65 parts of safflower, 50-55 parts of angelica sinensis, 55-65 parts of native copper, 50-60 parts of pseudo-ginseng, 50-60 parts of liquorice, 20-25 parts of keel and the like, and a plurality of auxiliary materials are used. Also discloses a method for decocting the plaster by the components. The invention has better treatment effect on traumatic injury and lower sensitization. Can be used for treating traumatic injury, fracture, injury of tendons and bones, swelling, pain, etc. Has effects of relieving swelling and pain, promoting blood circulation for removing blood stasis, relieving rigidity of muscles, activating collaterals, and relieving arthralgia.
INTRODUCTION: Seasonality in the incidence of stroke has been examined in numerous studies, yet data on whether it differs with age are limited. To fill this gap, we utilized a largescale dataset from Israel.
PATIENTS AND METHODS: We retrieved data of all hospitalizations for ischemic stroke (IS), transient ischemic attack (TIA) and intra cerebral hemorrhage (ICH) from 2000 to 2020. We maintained separate datasets for IS/TIA and ICH, divided into five age groups: 18-49, 50-59, 60-69, 70-79, and 80+. We modeled the monthly incidence using a generalized additive model. The seasonal effect was defined by the rate ratio (RR) of each month compared to the annual mean.
RESULTS: The analysis included 317,586 and 23,789 events of IS/TIA and ICH respectively. We found an interaction between age and seasonality, accounting for a phase shift with age in the seasonal pattern of IS/TIA incidence. For cases under 70 years, the peak was during summertime and the RRs increased with decreasing age, reaching 1.11 (95% CI 1.09-1.13) at the youngest age group. In contrast, among the elderly, a winter peak was observed and the RRs increased with age to 1.07 (95% CI 1.06-1.08) at the oldest age group. For ICH, a winter/autumn peak was identified and the RRs increased with age to 1.20 (95% CI 1.16-1.24).
CONCLUSIONS: Our finding of age-dependent seasonal patterns in the occurrence of stroke, suggests closer monitoring of cardiovascular risk factors during wintertime among elderly individuals. The mechanism governing the seasonal phase shift with age in IS/TIA incidence, requires further investigation.
The invention discloses an application of circPPM1F as a T1DM diagnosis and treatment target. Application of circPPM1F as a diagnostic marker in preparation of T1DM auxiliary diagnostic reagent. Use of an agent that inhibits circPPM1F in the manufacture of a medicament for the treatment of T1 DM. A pharmaceutical composition for treating T1DM, which comprises siRNA of circPPM1F and a drug carrier. The circPPM1F is obviously highly expressed in PBMC of a T1DM patient, and an ROC curve shows that the circPPM1F has considerable reliability as a diagnostic marker of T1 DM. The circPPM1F positively regulates the activation of macrophage TLR-MyD88 pathway, induces the expression of inflammatory factors and further damages the function of islet cells. This suggests that circPPM1F may be a new target for prevention and treatment of T1 DM.
Low back pain (LBP) is a major health and socioeconomic burden. LBP is usually a result of benign dysfunction and context that affects the patient's perception of pain and limits their activity and participation. At present there are no national clinical guidelines or best practice models of care in Sweden focused on the primary care of low back pain. Implementation of a model of LBP primary care based on international evidence-based guidelines is needed to improve care and patient outcomes in Sweden. This project aims to investigate the effectiveness of a best practice model of care (BetterBack) for the primary care management of LBP. A cluster randomised trial with dog leg design will be conducted in the Östergötland Health care region. The hypothesis is that the BetterBack model of care will result in significantly better patient and therapist reported outcomes as well as cost-effectiveness compared to current routine care. This by improved patient outcomes in terms of physical function, low back pain intensity, activity level, work and quality of life. Furthermore, improved care processes and knowledge support for physiotherapists can lead to a smaller proportion of patients requiring specialist care.
This is a multicenter, national, two-armed cluster-randomized controlled trial to evaluate the effect of a treat-to-target (T2T) strategy in in systemic lupus erythematosus (SLE) on damage progression and health related quality of life (HRQoL). The study centers will be assigned 1:1 to standard of care (SoC) or remission, defined as the absence of clinical disease activity (clinical SLEDAI =0) AND prednisolone ≤5mg/day AND physician global assessment (PGA) \<0.5 on a VAS 0-3. Patient with SLE \> 18 years of age who are not in remission will be eligible.

Per arm, 303 patients will be included. Intervention centers receive a standardized training on T2T and shared decision making (SDM). In the intervention centers, patients not on target enter a phase of tight control with 6-weekly visits and treatment adjustments (at least 4 visits) or until remission is reached and maintained. Patients in remission are reassessed every 12 weeks. In case of flare, they can re-enter tight control based on SDM. In the SoC arm, patients receive 3- to 6-monthly controls and treatment adjustments according to the physician's discretion. Study duration is 120 weeks using damage accrual and HRQoL as major outcomes.
The present invention provides a method for determining an adjustment prescription for an external fixation device fixed to an anatomical structure. The method comprises acquiring at least two digital radiological images of the external fixation device and the anatomical structure in different directions in an initial arrangement. The method further includes identifying fiducial markers of the external fixation device and axes of the anatomical structure in the at least two radiological images. The method further includes providing a virtual steerable three-dimensional model of the external fixation device and the anatomical structure. The method further includes providing an adjustment prescription for the strut assembly of the external fixation device based on the user-determined desired placement of the anatomical structure, the adjustment prescription repositioning the anatomical structure from the initial placement to the desired placement via at least one user-selected path point. The desired placement of the user-determined anatomy is determined by a three-dimensional model.
The invention discloses tea tree oil bath salt. The tea tree oil bath salt is prepared from, by weight, 30-50 parts of sea salt, 10-30 parts of sodium sulfate, 10-30 parts of sodium dihydrogen phosphate, 5-10 parts of peal powder, 5-10 parts of dry aloe glue, 1-5 parts of carboxymethylinulin natrium, 1-5 parts of cocamidopropyl betaine, 1-5 parts of sodium laneth sulfate, 0.5-3 parts of oleum menthae, 0.5-3 parts of eucalyptus oil, 1-5 parts of grape seed oil and 0.5-3 parts of tea tree oil. The preparing method of the tea tree oil bath salt comprises the steps that the dry aloe glue is prepared; secondly, the pearl powder is used for absorbing essence; thirdly, the tea tree oil bath salt is prepared. The tea tree oil bath salt is light green, can generate abundant bubbles with water, and has good cool and refreshing feelings and the function of boosting the spirit. A water solution is faintly acid to neutral and cannot hurt the skin. The tea tree oil bath salt has good moisturizing and whiting functions and can be used in a long term.
The present study measured serum levels of vitamin A (VA) and vitamin D (VD) in children with chronic tic disorders (CTD) and investigated their potential association with CTD and comorbidity of attention deficit hyperactivity disorder (ADHD) and the association of their co-insufficiencies or deficiencies with CTD symptoms. A total of 176 children (131 boys and 45 girls, median age of 9 years) with CTD were recruited as the CTD group. During the same period, 154 healthy children were selected as the healthy control (HC) cohort. Circulating retinol and 25-hydroxyvitamin D (25[OH]D) levels were measured for all participants using high-performance liquid chromatography (HPLC) and tandem mass spectrometry. The Yale Global Tic Severity Scale (YGTSS) was employed for the assessment of tic status and CTD impairment. The Swanson, Nolan, and Pelham Rating Scale (SNAP-IV) and the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) were used to evaluate comorbidity symptoms. CTD pediatric participants exhibited markedly diminished circulating retinol and 25(OH)D levels compared to HCs. Moreover, VA and VD deficiencies and their co-insufficiencies/deficiencies were more prevalent in CTD participants than HCs. Circulating 25(OH)D levels were inversely proportional to the YGTSS motor tic scores. YGTSS scores in CTD children with only VA or VD insufficiency or deficiency or with VA and VD co-insufficiency/deficiency did not differ from those in CTD children with normal VA and VD. CTD children with comorbid ADHD displayed reduced circulating retinol and 25(OH)D concentrations and elevated prevalence of VD deficiency compared to CTD participants without comorbid ADHD. Lower serum retinol content was intricately linked to the presence of elevated CTD and comorbid ADHD. VA and VD deficiencies and their co-insufficiencies/deficiencies were markedly enhanced in CTD pediatric participants compared to HCs. Lower VA concentration was linked to the presence of enhanced CTD and comorbid ADHD. Therefore, children with CTD, especially with comorbid ADHD, may be at a higher risk of VA or VD deficiency, which may prompt the clinicians to consider whether blood tests for VA and VD in CTD children would be helpful for clinical care.
A mixture of 20 cc bath water and 1 cc lavender oil will be used. lavender bath lasted about 10 minutes.
Accumulation of mucus in the airway involves the process of overproduction and reduced clearance of mucin glycoproteins. To date, little attention has been focused on mechanisms of mucin clearance from the airway. We hypothesize that there is enzymatic degradation of mucins ("mucinase activity") in the airway, which acts to break down mucins and facilitate their clearance. We further hypothesize that glycosidases function as mucinases by removing peripheral monosaccharides from oligosaccharides, including oligosaccharides on mucins. Removal of terminal or capping sugars on mucin side chains may be an important mechanism in mucin degradation and clearance from the lung. If mucinase activity exists in the airway then mucus collected from human subjects should demonstrate evidence of mucin degradation ex vivo, especially at 37º celsius. As part of our protocol we propose to examine changes in airway mucus ex vivo under different experimental conditions. Our primary readout will be measures of sputum rheology, namely viscosity and elasticity. Our consultant for this methodology will be Dr Susan Muller (Chemical Engineering, University of California, Berkeley). In order to conduct experimental studies in this way we will need multiple samples from the same subjects. Thus, up to 10 or more sputum samples per subject will be collected on different days. In addition, we are interested in the biochemical properties of sputum and saliva, specifically the composition of mucin molecules found in these fluids.
Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
The present invention relates to a traditional Chinese medicine for treating dermatosis and a preparation method thereof, which belongs to a Chinese patent medicine for treating dermatosis and a preparation method thereof. No. 1 medicine liquid is prepared from 69 wt% to 71 wt% of spirit, 15 wt% to 17 wt% of quicklime powder and 13 wt% to 15 wt% of edible alkli. No. 2 medicine liquid is prepared from 0.95 wt% to 2.2 wt% of aloe, 0.95 wt% to 2.3 wt% of rose flower, 0.53 wt% to 0.7 wt% of root of taiwan angelica and 95.4 wt% to 97 wt% of spirit. The preparation method comprises the steps: the quicklime powder is put into a glass bottle filled with the spirit; after being heated to liquid, the edible alkli is sealed in the glass bottle filled with the quicklime powder and the spirit; the mixture is agitated for one time every day, and the agitation is stopped 15 days later; dregs are filtered 10 days later to obtain the No. 1 medicine liquid; the spirit, the rose flower, the aloe and the root of taiwan angelica are immersed for 15 days, and dregs are filtered to obtain the No. 2 medicine liquid. The Chinese patent medicine for treating dermatosis has the advantage of no toxic or side effect, and has the obvious curative effect on tinea capitis, tinea corporis, red and white aphtha, mandible sore, deep-rooted boil, etc. The effective rate is more than 98 %, the cure rate is more than 70%, and the preparation method is simple.
Improper use may result in acceleration of bone age and premature closure of epiphyses. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. Precocious puberty has also been reported with use of testosterone.  
  
The safety and effectiveness of Testosterone Cypionate Injection have not been established in pediatric patients young than 12 years of age.